AQR Capital Management
FHTX icon

AQR Capital Management’s Foghorn Therapeutics FHTX Stock Holding History

AQR Capital Management’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$156K Buy
32,560
+19,010
+140% +$104K ﹤0.01% 3639
2025
Q4 		$73.2K Sell
13,550
-4,228
-24% -$19.2K ﹤0.01% 3485
2025
Q3 		$86.9K Sell
17,778
-80
-0.4% -$424 ﹤0.01% 3379
2025
Q2 		$83.9K Sell
17,858
-835
-4% -$3.49K ﹤0.01% 3206
2025
Q1 		$68.2K Buy
+18,693
New +$85.2K ﹤0.01% 3063
2023
Q1 		– Sell
-39,817
Closed -$254K – 2194
2022
Q4 		$254K Sell
39,817
-30,770
-44% -$232K ﹤0.01% 2020
2022
Q3 		$606K Buy
+70,587
New +$908K ﹤0.01% 1704

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

AQR Capital Management's FHTX Position: Q1 2026 in Review

AQR Capital Management increased its Foghorn Therapeutics (FHTX) stake by 140% in Q1 2026, buying an estimated $104K and bringing the position to 32,560 shares worth $156K. The position accounts for ﹤0.01% of the portfolio, ranked #3639.

AQR Capital Management first reported a position in FHTX in Q3 2022 and has held it in 7 quarters since. The position peaked at $606K in Q3 2022. 105 funds tracked by Wall St. Rank hold FHTX as of Q1 2026.

  • AQR Capital Management held 32,560 shares of Foghorn Therapeutics worth $156K as of Q1 2026.
  • AQR Capital Management bought 19,010 Foghorn Therapeutics shares in Q1 2026, an estimated $104K.
  • Foghorn Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #3639 holding.
  • AQR Capital Management first reported a position in Foghorn Therapeutics in Q3 2022 and has held it in 7 quarters since.
  • AQR Capital Management's Foghorn Therapeutics position peaked at $606K in Q3 2022.
  • 105 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.